Real-world effectiveness and tolerability of cannabidiol in pediatric and adult patients with developmental and epileptic encephalopathies: a retrospective single-center study

Background Developmental and epileptic encephalopathies (DEEs) are severe, drug-resistant epilepsies commonly associated with behavioral and cognitive impairment. Cannabidiol (CBD) is approved as adjunctive therapy for seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, but real-world evidence on outcomes beyond seizure control, and in patients treated outside these approved indications, remains limited. We performed a retrospective single-center study of pediatric and adult patients with DEEs who started adjunctive CBD between 2015 and 2025, to evaluate its real-world effectiveness and tolerability on seizure, behavioral, and cognitive outcomes at 3, 6, and 12 months. Results Fifty patients were included (mean age 22.1 ± 11.6 years; 58% female); 62% had combined focal and generalized seizures, and among generalized seizures, tonic–clonic seizures were the most frequent type (32%). A genetic etiology was identified in 48% of patients. Median monthly seizure frequency decreased from 31 at baseline to 16 at 6 months (p = 0.005) and 8 at 12 months (p = 0.007), and a ≥ 50% reduction in seizure frequency was achieved in 30.8%, 64.0%, and 48.0% of patients at 3, 6, and 12 months, respectively. Caregiver-reported behavioral improvement was noted in 34.8% and 33.3% of patients at 6 and 12 months, and cognitive improvement in 36.4% and 25.0%, respectively. At 6 months, cognitive improvement was associated with the absence of psychomotor delay (p = 0.011), a diagnosis of Dravet syndrome (p = 0.036), and lower intellectual disability severity (p = 0.005). Adverse events occurred in 50% of patients, most commonly somnolence; no serious adverse events were reported. Conclusions Adjunctive CBD was associated with a clinically meaningful reduction in seizure frequency, particularly for convulsive seizures. Improvements in behavioral and cognitive domains were observed in up to one-third of patients, supporting a broader clinical benefit beyond seizure control in this population.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-10852406/v1
Primary Topic
Epilepsy research and treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-world effectiveness and tolerability of cannabidiol in pediatric and adult patients with developmental and epileptic encephalopathies: a retrospective single-center study

Laura Abraira, Júlia Sala‐Coromina, Samuel López‐Maza, Miquel Raspall‐Chaure et al.
Research Square
Epilepsy research and treatment
preprint

Real-world effectiveness and tolerability of cannabidiol in pediatric and adult patients with developmental and epileptic encephalopathies: a retrospective single-center study

Laura Abraira, Júlia Sala‐Coromina, Samuel López‐Maza, Miquel Raspall‐Chaure, Daniel Campos, Paula Arranz, Teresa Jordà-Baleri, Isabel Pava-Bernat, Manuel Toledo, Elena Fonseca, Maria Garcés, Manuel Quintana, Estevo Santamarina
preprint en

Abstract

Background Developmental and epileptic encephalopathies (DEEs) are severe, drug-resistant epilepsies commonly associated with behavioral and cognitive impairment. Cannabidiol (CBD) is approved as adjunctive therapy for seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, but real-world evidence on outcomes beyond seizure control, and in patients treated outside these approved indications, remains limited. We performed a retrospective single-center study of pediatric and adult patients with DEEs who started adjunctive CBD between 2015 and 2025, to evaluate its real-world effectiveness and tolerability on seizure, behavioral, and cognitive outcomes at 3, 6, and 12 months. Results Fifty patients were included (mean age 22.1 ± 11.6 years; 58% female); 62% had combined focal and generalized seizures, and among generalized seizures, tonic–clonic seizures were the most frequent type (32%). A genetic etiology was identified in 48% of patients. Median monthly seizure frequency decreased from 31 at baseline to 16 at 6 months (p = 0.005) and 8 at 12 months (p = 0.007), and a ≥ 50% reduction in seizure frequency was achieved in 30.8%, 64.0%, and 48.0% of patients at 3, 6, and 12 months, respectively. Caregiver-reported behavioral improvement was noted in 34.8% and 33.3% of patients at 6 and 12 months, and cognitive improvement in 36.4% and 25.0%, respectively. At 6 months, cognitive improvement was associated with the absence of psychomotor delay (p = 0.011), a diagnosis of Dravet syndrome (p = 0.036), and lower intellectual disability severity (p = 0.005). Adverse events occurred in 50% of patients, most commonly somnolence; no serious adverse events were reported. Conclusions Adjunctive CBD was associated with a clinically meaningful reduction in seizure frequency, particularly for convulsive seizures. Improvements in behavioral and cognitive domains were observed in up to one-third of patients, supporting a broader clinical benefit beyond seizure control in this population.

Research Square
Vall d'Hebron Institut de Recerca (ES), Vall d'Hebron Hospital Universitari (ES)
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon